Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Millenium

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

New EC anti-smoking plans include ban on flavoured tobacco

Pictorial health warnings on cigarettes and regulation for e-cigarettes also proposed

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

- PMLiVE

ASH meeting hears of progress with myelofibrosis drugs

New studies suggest momentum is for use of Janus kinase (JAK) inhibitors

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Interview: Trevor Smith, Takeda

Takeda’s head of commercial operations for Europe and Canada talks about the integration of Nycomed and European market access

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links